RV
RV7.F Halozyme Therapeutics Inc
- Market cap
- EUR 10.4B
- P/E
- 26.6x
- P/B
- 101.40x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RV7.F undervalued?
Graham numberThe Graham number of Halozyme Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Halozyme Therapeutics Inc fundamental analysis
No fundamental analysis for Halozyme Therapeutics Inc yet.
Halozyme Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombin…
Full company profileHalozyme Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Halozyme Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 147M | 317M | 152M | 196M | 268M | 443M | 660M | 829M | 1.02B | 1.40B | 1.80B |
| Gross Profit | 113M | 285M | 142M | 150M | 224M | 362M | 521M | 637M | 856M | 1.17B | 1.48B |
| Operating Income | -83.2M | 81.0M | -69.3M | -67.6M | 144M | 276M | 268M | 338M | 551M | 803M | 1.02B |
| EBITDA | - | 85.8M | -59.4M | -56.6M | 153M | 259M | 309M | 452M | 657M | 573M | 1.17B |
| Net Income | -103M | 63.0M | -80.3M | -72.2M | 129M | 403M | 202M | 282M | 444M | 317M | 836M |
| EPS | - | 0.44 | -0.56 | -0.53 | 0.96 | 2.93 | 1.50 | 2.22 | 3.61 | 2.69 | 7.34 |
| Balance Sheet | |||||||||||
| Total Assets | 262M | 520M | 440M | 566M | 580M | 1.10B | 1.84B | 1.73B | 2.06B | 2.53B | 3.47B |
| Total Liabilities | 294M | 312M | 191M | 474M | 429M | 907M | 1.67B | 1.65B | 1.70B | 2.48B | 3.53B |
| Shareholders' Equity | -32.5M | 208M | 249M | 91.8M | 151M | 197M | 170M | 83.8M | 364M | 48.8M | -55.2M |
| Cash & Short-term Investments | 66.8M | 169M | 57.9M | 120M | 148M | 119M | 234M | 118M | 116M | 134M | 1.03B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -50.4M | 134M | -49.5M | -85.4M | 55.5M | 299M | 240M | 389M | 479M | 652M | 906M |
| Capital Expenditure | 3.14M | 1.35M | 4.66M | 4.04M | 2.50M | 1.46M | 4.81M | 15.3M | 10.7M | 295M | 14.6M |
| Free Cash Flow | - | 133M | -54.2M | -89.5M | 53.0M | 298M | 235M | 373M | 468M | 357M | 891M |
| Ratios | |||||||||||
| ROE | - | 30.2% | -32.3% | -78.7% | 85.5% | 204.5% | 119.0% | 336.0% | 122.1% | 649.2% | - |
| ROA | -39.4% | 12.1% | -18.2% | -12.8% | 22.3% | 36.5% | 11.0% | 16.2% | 21.5% | 12.5% | 24.1% |
| Net Profit Margin | -70.2% | 19.9% | -52.9% | -36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% | 46.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Halozyme Therapeutics Inc dividends
Halozyme Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Halozyme Therapeutics Inc
- Insiders 1.08%
- Institutions 98.92%
- Public & others 0.00%
- Shares outstanding 114M
- Free float 113M
Halozyme Therapeutics Inc company profile
- Company name
- Halozyme Therapeutics Inc
- Ticker
- RV7.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 423
- Fiscal year end
- December
- Address
- 12390 El Camino Real, San Diego, CA, United States, 92130
- Phone
- 858 794 8889
- Website
- halozyme.com
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics Inc management
10- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.President, CEO & Director · born 1963
- Mr. Mark Snyder Esq.Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary · born 1967
- Mr. Darren SnellgroveSenior VP & CFO
- Mr. Brian SweeneyChief Human Resources Officer · born 1964
- Mr. David A. Ramsay MBAPresident of Drug Delivery · born 1965
- Dr. Christopher Wahl M.B.A., M.D.Chief Scientific Officer
- Dr. Charles P. Theuer M.D., Ph.D.Chief Medical Officer · born 1964
- Mr. Paul SpenceChief Commercial Officer · born 1969
- Mr. Chase Coffman Ph.D.President of Hypercon
- Dr. Anna PutnamPresident of Aerocon